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• BRIEF REPORTS •
For IL-10 -819 genotypes, mean scores of fibrosis 
were A/A = 6.0, A/C = 2.2, and C/C = 1.0 (P = 0.020) 
though the inflammatory activity was not much different. 
No significant differences in HAI were noted among 
polymorphisms of other cytokines. Moreover, ALT and 
HCV RNA levels were not significantly different among 
different cytokine polymorphisms. There was a significant 
correlation of HAI and HCV RNA levels with the duration 
of disease. TGFβ -10 genotype CC patients had a 
better end of treatment response than those with other 
genotypes (P = 0.020). Sustained virological response 
to the treatment was not influenced by the cytokine 
polymorphism. No effect of other factors like viral load, 
degree of fibrosis, gender, steatosis, was observed on 
sustained virological response in this population infected 
with genotype 3.
CONCLUSION: There is no significant correlation 
between cytokine polymorphisms and HAI except for 
the polymorphisms of anti-inflammatory cytokine IL-10, 
which may influence hepatic inflammatory activity and 
fibrosis in patients with chronic hepatitis C genotype 3. 
Sustained virological response in this genotype does not 
seem to be influenced by cytokine gene polymorphisms. 
© 2005 The WJG  Press and  Elsevier  Inc.  All rights  reserved.
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HCV infection is a leading cause of  chronic liver disease 
worldwide. The infection leads to viral persistence and 
chronic disease in a very high proportion of  cases. 
Pathogenesis of  liver injury is not fully understood. 
There is a complex relationship between HCV and 
its host.  Liver lesions could be the result of  immune 
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Abstract
AIM: To investigate the association between cytokine 
gene polymorphism and disease status in chronic 
hepatitis C genotype 3 by liver biopsy, ALT, HCV RNA 
levels and response to treatment.
 
METHODS: Patients with chronic hepatitis C genotype 
3 were analyzed for single nucleotide polymorphisms of 
interleukin (IL)-10, IL-1 beta, interferon-gamma (IFN-γ), 
tumor necrosis factor-alpha (TNF-α) and transforming 
growth factor-beta (TGF-β) by polymerase chain reaction 
using sequence-specific oligonucleotide primers. Liver 
biopsies were assessed by modified histological activity 
index (HAI) scoring system using a scale of 0–18 for 
grading the necro-inflammatory activity and 0–6 for 
staging the fibrosis. HCV RNA levels were determined by 
bDNA assay. The patients were treated with interferon 
alpha and ribavirin for 6 mo. Sustained virological 
response was assessed 6 mo after the completion of the 
treatment.
RESULTS: Out of the 40 patients analyzed, 26 were 
males. Mean age was 40.5±12.5 years (range 18–
65 years). The frequencies of different dimorphic 
polymorphisms based on single nucleotide substitution 
were as follows: IL-10-1082 G/A 85%, A/A 12.5%, G/
G  2.5%; IL-10-819 A/C 87.5%, C/C 10%, A/A 2.5%; 
IL-10-592 C/A 72.5%, C/C 27.5%; IL-1 C 90%, U 10%; 
IFN-874 T/A 50%, T/T 27.5%, A/A 22.5%; TNF-308 
A/G 95%, G/G 5%; TGF-10 T/C 52.5%, C/C 35%, T/T 
12.5%. The mean grades of necro-inflammatory activity 
of different genotypes of IL-10 at promoter site -1082 
were A/A = 3.6, A/G = 5.0, and G/G = 10.0 and the 
difference was significant (P = 0.029). The difference in 
the stage of disease at a scale of 0–6 was A/A 0.8, A/G 
2.3, and G/G 4.0 (P = 0.079). The difference in the HAI 
seemed to be related to the presence of allele -1082G. 
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responses or cytopathic action of  the virus. Cytotoxic T 
cells and cytokines produced by both CD4+ (T helper) 
and cytotoxic T cells may be responsible for much of  the 
damage that occurs in the livers of  infected patients[1]. 
Two distinct patterns of  cytokine production may 
occur[2]. Type 1 responses are characterized by production 
of  interleukin-2 (IL-2), tumor necrosis factor-alpha 
(TNF-α) and interferon-gamma (IFN-γ), which are prime 
and maintain antigen-specific cellular immunity[3,4] and are 
important in defense against viruses. Type 2 responses are 
characterized by IL-4, IL-5, and IL-10, which promote 
humoral immune responses. An imbalance in helper T-cell 
type 1 (Th1) and type 2 (Th2) cytokines is suggested to 
play an important role in the pathogenesis of  chronic 
hepatitis C. The progressive liver injury seen in chronic 
HCV infection is associated with the upregulation of  
intrahepatic Th1-like cytokines. Intrahepatic IFN-γ and 
IL-2 mRNA expression is upregulated in chronic hepatitis 
C, while the expression of  IL-10, a Th2-like cytokine, is 
downregulated[5] . 
Intrahepatic CD4+ T cells play a pathogenetic role in 
the hepatic injury of  HCV infection[6]. Vigorous HCV-
specific CD4+ Th1 response, particularly against the 
nonstructural proteins of  the virus, may be associated with 
viral clearance and protection from disease progression[7]. 
Patients without viremia after HCV infection frequently 
have strong Th lymphocyte responses of  the Th1 type 
to multiple HCV antigens many years after the onset of  
infection, whereas antibody responses are less marked. 
These results suggest that control of  HCV replication 
may depend on effective Th lymphocyte activation[8,9]. 
There is also an enhanced Th2 response during chronic 
HCV infection, which may partly be responsible for the 
persistence of  HCV infection. 
In addition to the altered intrahepatic cytokine 
expression, there might be a significant correlation 
between circulating cytokines and degree of  inflammation 
in the liver. One study has shown such a correlation 
between baseline TNF levels and histologic grading 
score of  hepatitis[10]. The maximal capacity of  cytokine 
production varies between individuals and may correlate 
with polymorphism in cytokine gene promoters. The 
objectives of  our study were to analyze the role of  allelic 
or genotype variations of  IL-10, IL-1 beta, IFN-γ, TNF-α 
and TGF-β and its association with hepatocellular injury as 
suggested by liver biopsy and ALT and treatment outcome. 
We selected genotype 3 for this study which is the main 
genotype in our country.
MATERIALS AND METHODS
Out of  the 40 patients analyzed, 26 were males. Mean age 
was 40.5±12.5 years (range 18-65 years). The participants 
did not receive interferon therapy and had neither co-
infection with human immunodeficiency virus and 
hepatitis B virus nor other associated forms of  chronic 
liver disease. 
Quantitative serum HCV RNA was determined by 
bDNA assay (Bayer, USA) according to the manufacturer’
s instructions.  The minimum quantification limit of  the 
assay was 3 000 HCV RNA copies/mL serum. HCV geno-
typing was performed using PCR and reverse hybridization 
assay (Innogenetics, Belgium). All patients included in 
this study were of  HCV genotype 3. For cytokine gene 
polymorphism, DNA was extracted by proteinase K 
digestion from peripheral mononuclear cells, followed by 
phenol chloroform extraction and ethanol precipitation. 
After amplification polymorphisms in IL-10 (592, 819, 
1082), IL-1β (-511), IFNγ (874), TNFα (308) and TGF 
(codon25) were examined as described previously[11-13]. 
The number in parenthesis indicates the location of  the 
polymorphism on the DNA sequence. Briefly, single 
nucleotide polymorphisms (SNPs) were determined using 
sequence specific oligonucleotide primers. Each PCR 
reaction consisted of  1× PCR buffer, 0.2 mmol dNTPs. 
Concentration of  MgCl2 varied with the type of  SNP 
examined, 50 ng of  each polymorphism specific primer, 
1 U of  Taq  polymerase in a final volume of  10 µL. To 
monitor PCR inhibition, growth hormone gene was 
simultaneously amplified as an internal control. Thermal 
cycling was performed in a Perkin-Elmer 9700 thermal 
cycler. Following PCR amplification, amplicons were 
stained with ethidium bromide and visualized on a UV 
transilluminator. The size of  product generated in each 
PCR assay was ascertained and scored as positive/negative 
for the presence/absence of  a particular polymorphism. 
The PCR product obtained with IL-1β-511 specific 
primers was digested with the restriction enzyme AvaII. 
The digested product was then visualized for the presence 
of  restriction fragments. 
Liver biopsy specimens were analyzed by a single 
pathologist, who was unaware of  the patient’s identity, 
treatment regimen, response, or timing of  the biopsy 
relative to the treatment. Liver biopsies were assessed by 
modified histological activity index (HAI) scoring system[14] 
using a scale of  0-18 for grading and 0-6 for staging. 
Degree of  steatosis was scored at a scale of  0-3. Presence 
or absence of  lymph follicles was also documented. 
Duration of  disease was determined by calculating 
time interval from the exposure to a possible risk factor. 
Patients were treated with standard doses of  interferon 
alpha (3 mega units subcutaneous, thrice a week) and 
ribavirin (800-1 200 mg/d) for 6 mo and followed up for 
another 6 mo. HCV RNA was repeated 6 mo after the 
treatment to document sustained response. 
Statistical analysis
Statistical analysis was performed by two-tailed tests. P 
values were calculated by one-way analysis of  variance 
(ANOVA), Pearson’s χ2 and Spearman’s rho correlation 
tests.  P<0.05 was considered statistically significant.
RESULTS
The frequencies of  different dimorphic polymorphisms 
based on single nucleotide substitution were as follows: 
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IL10-1082 G/A 85%, A/A 12.5%, G/G  2.5%; IL10-819 
A/C 87.5%, C/C 10%, A/A 2.5%; IL10-592 C/A 72.5%, 
C/C 27.5%; IL-1 C 90%, U 10%; IFN-874 T/A 50%, 
T/T 27.5%, A/A 22.5%; TNF-308 A/G 95%, G/G 
5%; TGF-10 T/C 52.5%, C/C 35%, T/T 12.5%. The 
mean grades of  necro-inflammatory activity at a scale of  
0-18 for different genotypes of  IL10 at promoter site 
-1082 were A/A = 3.6, A/G = 5.0, and G/G = 10.0 and 
the difference was significant (P = 0.029). The difference 
in the stage of  disease at a scale of  0-6 was A/A 0.8, A/G 
2.3, and G/G 4.0 (P = 0.079). This difference in the HAI 
seemed to be related to the presence of  allele -1082G. For 
IL 10 -819 genotypes the mean scores of  fibrosis were 
A/A = 6.0, A/C = 2.2, and C/C = 1.0 (P = 0.020) though 
the inflammatory activity was not much different. 
No significant differences in the degree of  necro-
inflammatory activity and fibrosis were noted among the 
polymorphisms of  other cytokines (Table 1). Moreover, 
ALT and HCV RNA levels were not significantly different 
among different cytokine polymorphisms. There was a 
significant correlation of  duration of  disease with grade 
and stage of  disease and HCV RNA levels (P = 0.017, 0.018, 
and 0.015 respectively with Spearman’s rho test).  
Out of  the 40 patients, 34 remained under the follow-
up. These patients completed the 6-mo treatment with 
interferon and ribavirin.  HCV RNA was repeated 6 mo 
after the treatment to document the sustained response 
and the effect of  cytokine gene polymorphism. TGFβ 
-10 genotype CC patients had a better end of  treatment 
response than those with other genotypes (P = 0.020), 
though there was no difference in the sustained virological 
response. No effect of  other factors like viral load, 
degree of  fibrosis, gender, steatosis, was observed on the 
sustained virological response in this population infected 
with genotype 3.
DISCUSSION
Approximately 80-90% of  patients acutely infected with 
hepatitis C virus develop persistent infection, about one-
half  of  them have elevated transaminases indicative 
of  ongoing liver inflammation[15]. In the context of  an 
inflammatory response against the virus, variable cytokine 
response of  the host may be responsible for the variable 
liver damage. Moreover, the cause of  viral persistence 
during HCV infection may be the development of  a 
weak antiviral immune response to the viral antigens, 
with corresponding inability to eradicate infected cells or 
insensitivity of  the virus to such cytokines or insufficient 
production of  cytokines [16]. Thus, the continuing 
inflammation results in liver damage in the absence of  
complete virologic recovery[17].
Studies have shown that active liver injury in chronic 
hepatitis C patients is associated with increased circulating 
Th1 cytokine IL-2 but not with Th2 cytokine IL-10[18]. It 
has also been shown by some workers that serum alanine 
transaminase and the hepatic fibrosis levels are related 
directly to the frequencies of  peripheral memory effector 
CD8(+) T cells producing IFN-γ (Tc1), but inversely to 
the frequencies of  those producing both IL-4 and IL-10 
(Tc2)[19]. Moreover, most liver-infiltrating T cells in chronic 
hepatitis C are type 1 cells. Studies to date in liver tissue 
showed that intrahepatic mRNA for type 1-like cytokines, 
such as IL-1β, IL-2, IL-6, IL-8, TNF-α, and IFN-γ were 
upregulated in chronic HCV infection[20]. The level of  
expression of  type 1 cytokines, such as IL-2 and IFN-γ, is 
correlated with the degree of  histologic injury as well as 
the likelihood of  non-responsiveness to IFN-α therapy[21]. 
The presence of  an ongoing cellular immune response 
probably also contributes to the process of  hepatic 
fibrosis. Kupffer cells can be activated by the production 
of  cytokines such as TNF-α, which in turn produce 
TGF-β[22]. 
 Serum levels of  different cytokines may not give the 
true picture of  what is going on in the liver. For example, 
the mean IL2Rs and IFN serum levels are much higher 
in patients with anti-HCV than in the control group, 
Cytokine gene 
polymorphism
ALT (upper limit 
normal)
HCV RNA level Grade of 
inflammation





IL 10 -1082 0.636 0.241 0.029 0.079 0.267 0.848 0.078 0.331
(GA, AA, GG)
IL 10 -819 0.794 0.781 0.412 0.020 0.57 0.295 0.063 0.331
(AC, CC, AA)
IL 10 -592 0.582 0.198 0.243 0.281 0.551 0.626 0.416 0.283
(CA, CC)
IFNγ -874 0.389 0.848 0.919 0.921 0.955 0.382 0.21 0.933
(AA, TT, TA)
TNFα -308 0.952 0.436 0.777 0.307 0.32 0.85 0.674 0.451
(AG, GG)
TGFβ -10 0.734 0.72 0.386 0.959 0.232 0.643 0.026 0.206
(CC, TC, TT)
IL 1 (C/U) 0.144 0.591 0.964 0.826 0.326 0.836 1.00 1.00
Table 1 Statistical significance of effects of cytokine gene polymorphisms on different parameters
P values were calculated by ANOVA and Pearson’ s χ2 test. Statistically significant values. IL: interleukin; IFNγ: interferon gamma; TNFα: tumor necrosis factor 
alpha; TGFβ:  transforming growth factor beta.
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whereas the mean IL4 and IL6 levels are lower in patients 
infected with HCV[23]. Another study shows the higher 
levels of  serum IL-1β, IL-4 and IL-6 (0.221, 0.104 and 
1.393 pg/mL) in all HCV patients than in healthy adults 
(0.188, 0.025 and 0.600 pg/mL)[24].
Sustained response to interferon and ribavirin, defined 
as undetectable HCV RNA at 6 mo after discontinuation 
of  therapy, is achievable in 30-60% of  treated patients[25,26]. 
Predictors of  response include viral factors such as viral 
genotypes, viral load and early disappearance of  HCV 
RNA after initiation of  therapy, while the host factors 
include gender, age and degree of  fibrosis[25-27].   In recent 
years, increasing attention has been drawn to the role 
of  host variation in cytokine levels in inflammatory and 
immune responses. Polymorphisms in genes encoding 
immunoregulatory proteins, proinflammatory cytokines, 
and fibrogenic factors may affect the production of  these 
factors and influence disease progression in patients 
with chronic liver disease due to alcohol, primary biliary 
cirrhosis, or hepatitis C[28].
There might be an association of  cytokine gene 
polymorphism and susceptibility to hepatitis C infection. 
Hohler et al[29]  have reported such an association with the 
polymorphism at the TNFα promoter. The TNF promoter 
variants TNF2 (-238A) and TNF3 (-308A) confer a 3.2-fold 
and 5.1-fold risk of  cirrhosis respectively (P = 0.03 for 
both). Reciprocal effects have been observed with several 
TNF alleles and haplotypes defined by the -238 G/A and 
-308 G/A dimorphic sequences, thus polymorphisms in 
the TNF alpha promoter appear to be associated with the 
variability in the histological severity of  chronic hepatitis 
C infection[30]. In our study done on hepatitis C genotype 
3 patients, no such effect of  TNFα -308 variability was 
observed. 
Interleukin (IL)-10 is a cytokine that downregulates the 
proinflammatory response and has a modulatory effect 
on hepatic fibrogenesis and is a potent anti-inflammatory 
Th2 cytokine that downregulates the expression of  major 
histocompatibility complex (MHC) class I and class II 
molecules, as well as the production of  Th1 cytokines[31-36]. 
IL-10 levels differ widely between individuals, possibly 
because of  polymorphisms in the promoter region 
of  the IL-10 gene[37,38]. Specifically, three SNPs in the 
promoter (at positions -1082, -819, and -592 relative to 
the transcription start site) form three SNP combinations 
(ATA, ACC, GCC), which are associated with differential 
IL-10 expression[38-40]. It is reasonable to assume that 
hepatitis C patients who produce high levels of  IL-10 
have less hepatocellular injury and less ability to control 
infection and patients with low secretion of  IL-10 have a 
better ability to eliminate the hepatitis infection. Perhaps 
low IL-10 production can skew the immune system into 
the Th1 type of  response, facilitating the clearance of  
viral load. -1082A allele is associated with reduced IL-10 
production in vitro[39]. In our study, individuals who were 
homozygous for IL-10 AA at position -1082 had a lower 
HAI. 
It has been shown that hepatitis C patients, genotyped 
as high IL-10 producers, have a poor response to IFN-α 
therapy[40]. Such polymorphisms may also predict the 
sustained viral response to antiviral therapy[41]. These 
patients may benefit from additional treatment strategies 
designed to enhance T-helper type 1 (Th1) response. In 
one study, the interleukin-10 -1082 G/G genotype was 
identified more frequently in patients than in controls 
(P = 0.048). The patients exhibiting transforming growth 
factor-beta 1+29 (codon 10) C/C genotype variables were 
less likely to respond to treatment than patients with the 
T/T or T/C genotypes[42]. Liver transplant recipients, who 
are genotyped as having a low production profile of  IL-10, 
are more prone to rejection and less likely to have hepatitis 
C recurrence[43]. The IL-1beta-31 genotype T/T or the 
IL-1beta-511/-31 haplotype C/T is associated with the 
presence of  HCC in Japanese patients with chronic HCV 
infection[44]. 
However, not all the studies favor such effect of  
polymorphisms. Three members of  the interleukin-1 gene 
family (IL-1A, IL-1B and IL-1RN), three polymorphic sites 
in the interleukin-10 gene promoter (-1082, -819, -592) 
and two in the TNF-α promoter (-308, -238) were studied 
in two independent DNA banks, each with appropriate 
controls. Standard PCR-based genotyping techniques were 
used. No significant difference in the distribution of  any 
of  the polymorphisms has been found in either study 
set[45]. 
We, in this study, determined SNP at position -1082, 
-819 and -592 in case of  IL-10, -874  for IFN-γ, -308 
for TNF-α, -10 for TGF-β and  IL-1 C/ U and analyzed 
the frequency of  their distribution and correlation with 
the ALT and HCV RNA levels, HAI and response to 
treatment. In our series, we selected genotype 3 patients 
because this is the main genotype in our region and 
not enough data are available on the influence of  host 
cytokine gene polymorphisms of  this viral genotype. 
Another reason of  selecting a single genotype was to 
make the group uniform as different genotypes have 
different response rates to antiviral therapy and influence 
of  cytokines may also be different. We could not find 
any significant difference in the cytokine genotype profile 
while analyzing different variables except for some 
influence of  polymorphisms of  IL-10 on liver histology. 
These polymorphisms did not modulate the response to 
interferon plus ribavirin therapy. This may be due to the 
small sample size or the fact that viral genotype 3 is easy to 
treat genotype in any case.  
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